In a new study published by the journal, ACS Chemical Biology, scientists at the Scripps Research Institute have developed a new chemical compound which has been shown to block the presence of PRMT1, an enzyme linked to inflammation in individuals suffering from arthritis.
The study findings will be useful to scientists who are developing new drug treatments for PRMT1-related ailments and for targeting specific enzymes in the human body. It also moves scientists one step closer to identifying the enzyme responsible for nearly all arginine methylation present in mammalian cells.
To date scientists have been unable to distinguish between compounds inhibiting PRMT1 and those blocking the larger PRMT family of enzymes. This was largely due to the fact that scientists could not distinguish between PRMT1 and the 10 other PRMT enzymes due to their structural and biochemical similarities.
As research continues to explore the link between the development of these enzymes and inflammation, individuals suffering from symptoms relating to inflammation seek out remedies to alleviate their pain. There are currently countless prescription anti-inflammatories available on the market as well as a few supplements.
Nexrutine, an all-natural dietary supplement produced from the proprietary blend of actives extracted from the bark of Phellodendron amurense, acts to inhibit enzymes related to inflammation and is shown to safely and effectively help avoid or relieve the general aches and pains associated with physical activity or over-exertion.